X4 Pharmaceuticals (NASDAQ:XFOR) Downgraded to Sell Rating by Wall Street Zen

X4 Pharmaceuticals (NASDAQ:XFOR) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

Several other brokerages also recently commented on XFOR. Zacks Research downgraded X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. HC Wainwright set a $3.50 target price on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 13th. Stifel Nicolaus set a $7.50 price target on shares of X4 Pharmaceuticals in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, November 24th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $33.67.

X4 Pharmaceuticals Price Performance

XFOR stock opened at $3.68 on Friday. The stock has a market cap of $321.78 million, a PE ratio of -0.36 and a beta of 0.51. X4 Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $26.83. The company has a 50-day moving average price of $3.52 and a 200 day moving average price of $2.98. The company has a current ratio of 5.65, a quick ratio of 5.48 and a debt-to-equity ratio of 1.23.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.10. The business had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.05 million. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%. Equities research analysts anticipate that X4 Pharmaceuticals will post -0.68 earnings per share for the current year.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, Chairman Adam R. Craig acquired 86,206 shares of the stock in a transaction that occurred on Thursday, October 23rd. The stock was bought at an average cost of $2.90 per share, with a total value of $249,997.40. Following the completion of the purchase, the chairman directly owned 376,087 shares in the company, valued at $1,090,652.30. The trade was a 29.74% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.37% of the stock is owned by insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its stake in shares of X4 Pharmaceuticals by 9.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock valued at $114,000 after purchasing an additional 43,320 shares in the last quarter. Kingdon Capital Management L.L.C. lifted its holdings in X4 Pharmaceuticals by 41.8% during the first quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company’s stock worth $1,655,000 after buying an additional 2,063,000 shares during the period. Pale Fire Capital SE boosted its position in X4 Pharmaceuticals by 45.2% during the 1st quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock valued at $481,000 after acquiring an additional 633,398 shares in the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at $326,000. Finally, Rosalind Advisors Inc. bought a new position in shares of X4 Pharmaceuticals in the 3rd quarter worth $5,283,000. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.